The Novo Nordisk Foundation’s project to explore food processing has created some controversy of late. Initially, the project was framed as ‘the next generation’ of the ‘Nova’ classification, with its ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

German business-software group SAP SAP-3.34%decrease; red down pointing triangle claimed the top spot as Europe’s largest company by market value, dethroning Danish pharmaceutical giant Novo ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

At 0900 GMT, SAP had a market cap of $340 billion, slightly more than Novo Nordisk, according to Reuters calculations using LSEG Workspace data.SAP is Euro Software maker SAP unseats Novo Nordisk ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount. The Danish drugmaker launched NovoCare ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

National Security Adviser Eduardo Año denied Thursday that he had a hand in the supposed "conspiracy" that led to the arrest of former president Rodrigo Duterte last week. During a hearing of the ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy ...

Novo Nordisk has officially entered the direct-to-consumer (DTC) platform game. The Danish drugmaker unveiled NovoCare Pharmacy on Wednesday morning, offering home shipments of the popular GLP-1 ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to ...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...